JP2020534812A - 改良された相同組換えおよびその組成物のための方法 - Google Patents

改良された相同組換えおよびその組成物のための方法 Download PDF

Info

Publication number
JP2020534812A
JP2020534812A JP2020513724A JP2020513724A JP2020534812A JP 2020534812 A JP2020534812 A JP 2020534812A JP 2020513724 A JP2020513724 A JP 2020513724A JP 2020513724 A JP2020513724 A JP 2020513724A JP 2020534812 A JP2020534812 A JP 2020534812A
Authority
JP
Japan
Prior art keywords
nucleic acid
protein
dna
regulatory
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020513724A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534812A5 (https=
Inventor
シークアン リャン
シークアン リャン
ロバート ポッター
ロバート ポッター
ランシャ ポン
ランシャ ポン
Original Assignee
ライフ テクノロジーズ コーポレイション
ライフ テクノロジーズ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライフ テクノロジーズ コーポレイション, ライフ テクノロジーズ コーポレイション filed Critical ライフ テクノロジーズ コーポレイション
Publication of JP2020534812A publication Critical patent/JP2020534812A/ja
Publication of JP2020534812A5 publication Critical patent/JP2020534812A5/ja
Priority to JP2023145587A priority Critical patent/JP2023168355A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/95—Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2020513724A 2017-09-08 2018-09-07 改良された相同組換えおよびその組成物のための方法 Pending JP2020534812A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023145587A JP2023168355A (ja) 2017-09-08 2023-09-07 改良された相同組換えおよびその組成物のための方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762555862P 2017-09-08 2017-09-08
US62/555,862 2017-09-08
US201762568661P 2017-10-05 2017-10-05
US62/568,661 2017-10-05
US201762574936P 2017-10-20 2017-10-20
US62/574,936 2017-10-20
US201862626792P 2018-02-06 2018-02-06
US62/626,792 2018-02-06
US201862717403P 2018-08-10 2018-08-10
US62/717,403 2018-08-10
PCT/US2018/049966 WO2019051237A1 (en) 2017-09-08 2018-09-07 ENHANCED RECOMBINANT RECOMBINATION METHODS AND COMPOSITIONS THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023145587A Division JP2023168355A (ja) 2017-09-08 2023-09-07 改良された相同組換えおよびその組成物のための方法

Publications (2)

Publication Number Publication Date
JP2020534812A true JP2020534812A (ja) 2020-12-03
JP2020534812A5 JP2020534812A5 (https=) 2021-10-14

Family

ID=63714051

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020513724A Pending JP2020534812A (ja) 2017-09-08 2018-09-07 改良された相同組換えおよびその組成物のための方法
JP2023145587A Pending JP2023168355A (ja) 2017-09-08 2023-09-07 改良された相同組換えおよびその組成物のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023145587A Pending JP2023168355A (ja) 2017-09-08 2023-09-07 改良された相同組換えおよびその組成物のための方法

Country Status (5)

Country Link
US (1) US20190119701A1 (https=)
EP (1) EP3679143A1 (https=)
JP (2) JP2020534812A (https=)
CN (2) CN119570864A (https=)
WO (1) WO2019051237A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
CN109477130B (zh) 2016-07-01 2022-08-30 微软技术许可有限责任公司 通过迭代dna编辑的存储
US11359234B2 (en) 2016-07-01 2022-06-14 Microsoft Technology Licensing, Llc Barcoding sequences for identification of gene expression
US20180004537A1 (en) 2016-07-01 2018-01-04 Microsoft Technology Licensing, Llc Molecular State Machines
WO2019118921A1 (en) 2017-12-14 2019-06-20 Flodesign Sonics, Inc. Acoustic transducer drive and controller
WO2019204226A1 (en) * 2018-04-16 2019-10-24 University Of Massachusetts Compositions and methods for improved gene editing
WO2020072699A1 (en) * 2018-10-02 2020-04-09 Exosome Therapeutics, Inc. Exosome loaded therapeutics for treating sickle cell disease
US12312584B2 (en) * 2018-10-02 2025-05-27 Exosome Therapeutics, Inc. cGMP exosome loaded therapeutics for treating sickle cell disease
EP3870604B1 (en) 2018-10-26 2022-11-23 F. Hoffmann-La Roche AG Multispecific antibody screening method using recombinase mediated cassette exchange
CN111304248B (zh) * 2018-12-25 2021-08-24 百奥赛图江苏基因生物技术有限公司 人源化细胞因子il15基因改造非人动物的构建方法及应用
CN113661173B (zh) 2019-03-29 2024-10-01 豪夫迈·罗氏有限公司 通过以限定的组织形式靶向整合多个表达盒来产生表达FcRn的细胞的方法
WO2020206162A1 (en) * 2019-04-03 2020-10-08 Regeneron Pharmaceuticals, Inc. Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
US20230193322A1 (en) * 2019-04-16 2023-06-22 Arizona Board Of Regents On Behalf Of Arizona State University CAS9 Fusion Proteins and Related Methods
WO2020257684A1 (en) * 2019-06-20 2020-12-24 University Of Massachusetts Compositions and methods for improved gene editing
JP7579817B2 (ja) 2019-07-03 2024-11-08 インテグレーティッド ディーエヌエイ テクノロジーズ インコーポレーティッド Ｃｒｉｓｐｒで導入された二本鎖ｄｎａ切断修復の同定、特徴付けおよび定量化
US20210079387A1 (en) * 2019-08-27 2021-03-18 The Jackson Laboratory Cleavage-resistant donor nucleic acids and methods of use
US20220275400A1 (en) * 2019-08-30 2022-09-01 The Trustees Of Columbia University In The City Of New York Methods for scalable gene insertions
JP7762651B2 (ja) * 2019-10-24 2025-10-30 インテグレーティッド ディーエヌエイ テクノロジーズ インコーポレーティッド 修飾二重鎖ドナー鋳型
US20230086199A1 (en) * 2019-11-26 2023-03-23 The Broad Institute, Inc. Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
JP2024513087A (ja) * 2021-04-07 2024-03-21 アストラゼネカ・アクチエボラーグ 部位特異的改変のための組成物及び方法
EP4083227A1 (en) * 2021-04-29 2022-11-02 4basebio, S.L.U. Linear dna with enhanced resistance against exonucleases
JP2024533311A (ja) * 2021-09-08 2024-09-12 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー ゲノムを調節するための方法及び組成物
CN115029277B (zh) * 2022-06-24 2023-08-22 四川省烟草公司凉山州公司 一株耐酸抗青枯病的假蕈状芽孢杆菌
WO2025171070A1 (en) * 2024-02-06 2025-08-14 Integrated Dna Technologies, Inc. Optimized spcas9 proteins for efficient genome editing in eukaryotic cells

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001517939A (ja) * 1997-03-14 2001-10-09 ライフ テクノロジーズ，インコーポレイテッド ペプチドによって増強されるトランスフェクション
US20140315985A1 (en) * 2013-03-14 2014-10-23 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
JP2016509063A (ja) * 2013-02-25 2016-03-24 サンガモ バイオサイエンシーズ， インコーポレイテッド ヌクレアーゼ媒介性遺伝子破壊を増強するための方法および組成物
JP2016515401A (ja) * 2013-04-16 2016-05-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ラットゲノムの標的改変
JP2016539655A (ja) * 2013-12-11 2016-12-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ゲノムの標的改変のための方法及び組成物
WO2017066707A1 (en) * 2015-10-14 2017-04-20 Life Technologies Corporation Ribonucleoprotein transfection agents

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5334575A (en) 1992-12-17 1994-08-02 Eastman Kodak Company Dye-containing beads for laser-induced thermal dye transfer
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US5888795A (en) 1997-09-09 1999-03-30 Becton, Dickinson And Company Thermostable uracil DNA glycosylase and methods of use
US7592434B2 (en) 2003-04-04 2009-09-22 Verenium Corporation Pectate lyases, nucleic encoding them and methods for making and using them
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
US20120329067A1 (en) 2010-01-22 2012-12-27 Barbas Iii Carlos F Methods of Generating Zinc Finger Nucleases Having Altered Activity
ES2388020B1 (es) * 2011-03-10 2013-10-01 Universitat De Girona Proteínas recombinantes con efecto antitumoral.
WO2012168307A2 (en) * 2011-06-07 2012-12-13 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Improved recombination efficiency by inhibition of nhej dna repair
WO2013152220A2 (en) 2012-04-04 2013-10-10 Life Technologies Corporation Tal-effector assembly platform, customized services, kits and assays
AU2013359262C1 (en) * 2012-12-12 2021-05-13 Massachusetts Institute Of Technology CRISPR-Cas component systems, methods and compositions for sequence manipulation
EP3470089A1 (en) * 2013-12-12 2019-04-17 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
MX2016007797A (es) * 2013-12-19 2016-09-07 Amyris Inc Metodos para integracion genomica.
RS60359B1 (sr) * 2014-06-06 2020-07-31 Regeneron Pharma Postupci i kompozicije za modifikovanje ciljanog lokusa
EP4710943A3 (en) * 2015-08-28 2026-04-29 Molecular Transfer, Inc. Transfection complexes and methods of using the same
CN108779074A (zh) * 2016-03-01 2018-11-09 分子传递有限公司 植物病毒移动蛋白和其使用方法
WO2018013932A1 (en) * 2016-07-15 2018-01-18 Salk Institute For Biological Studies Methods and compositions for genome editing in non-dividing cells
US20200299729A1 (en) * 2017-09-08 2020-09-24 Life Technologies Corporation Methods for improved homologous recombination and compositions thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001517939A (ja) * 1997-03-14 2001-10-09 ライフ テクノロジーズ，インコーポレイテッド ペプチドによって増強されるトランスフェクション
JP2016509063A (ja) * 2013-02-25 2016-03-24 サンガモ バイオサイエンシーズ， インコーポレイテッド ヌクレアーゼ媒介性遺伝子破壊を増強するための方法および組成物
US20140315985A1 (en) * 2013-03-14 2014-10-23 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
JP2016515401A (ja) * 2013-04-16 2016-05-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ラットゲノムの標的改変
JP2016539655A (ja) * 2013-12-11 2016-12-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ゲノムの標的改変のための方法及び組成物
WO2017066707A1 (en) * 2015-10-14 2017-04-20 Life Technologies Corporation Ribonucleoprotein transfection agents

Also Published As

Publication number Publication date
US20190119701A1 (en) 2019-04-25
WO2019051237A1 (en) 2019-03-14
JP2023168355A (ja) 2023-11-24
CN119570864A (zh) 2025-03-07
EP3679143A1 (en) 2020-07-15
CN111315889A (zh) 2020-06-19
US20240247286A1 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
JP2023168355A (ja) 改良された相同組換えおよびその組成物のための方法
US20240247262A1 (en) Crispr/cas system and method for genome editing and modulating transcription
JP7220737B2 (ja) 標的ゲノム修飾を増強するためのプログラム可能なｄｎａ結合タンパク質の使用
JP7559005B2 (ja) 真核ゲノム修飾のための操作されたＣａｓ９システム
US20250154531A1 (en) Methods for improved homologous recombination and compositions thereof
ES2901629T3 (es) Uso de dominios de proteínas de interacción con el nucleosoma para mejorar la modificación dirigida del genoma
KR102004076B1 (ko) 3-성분 crispr/cas 복합체 시스템 및 그 용도
CN109415729B (zh) 具有降低毒性的基因编辑试剂
JP2020530992A (ja) Ｃｒｉｓｐｒ／ｃａｓアクチベーターシステムのための合成ガイドｒｎａ
JP2016523084A (ja) 標的組込み
WO2017107898A2 (en) Compositions and methods for gene editing
US20230128316A1 (en) Hairpin loop ended self-complementary double-stranded covalently closed linear dna vector, manufacturing system and process, and uses of said resulting dna vector
US12612650B2 (en) Methods for improved homologous recombination and compositions thereof
HK40027119A (en) Methods for improved homologous recombination and compositions thereof
HK40029778A (en) Methods for improved homologous recombination and compositions thereof
HK40093157A (zh) 使用可编程dna结合蛋白增强靶向基因组修饰
EA048319B1 (ru) СКОНСТРУИРОВАННЫЕ СИСТЕМЫ CasX
HK40040051A (en) Engineered cas9 systems for eukaryotic genome modification

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230313

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230907

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231018

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260304